65,437 trials
Disorder of Amniotic Cavity and/or Membrane
Primary: Cervical Shortening — 27.45; 29.61; 23.30; 23.88 millimeters
Anemia
Primary: Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period — 11.29; 11.33; 0.15; -0.03 g/dL
Influenza · Swine-origin A/H1N1 Influenza
Primary: Number of Participants With Detectable Antibodies Before and Following Vaccination With Either Adjuvanted or Non-adjuvanted A/H1N1 Pandemic Vaccine or a Placebo: Age 18…
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) of Groups by FDG Response at Day 56 — 28.1; 12.1 weeks — p=0.017
Candidiasis
Primary: Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT) — 170; 33 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 1.186…
Rheumatoid Arthritis
Primary: American College of Rheumatology 20 Response (ACR20) — 20; 15; 17; 34 Participants
Type 2 Diabetes Mellitus
Primary: Postprandial Glycemic Incremental Area Under the Curve — 739; 759 mmol/L / 2hr
Stroke · Muscle Spasticity · Motor Neuron Disease
Primary: Change From Baseline in Forced Vital Capacity (FVC) — 2.889; 3.068; 2.923; 0.057 Liters of air
Major Depressive Disorder
Primary: Change From Baseline in the Apathy Evaluation Scale - Clinician Rated Version (AES-C) Total Score at Week 8 — -13.88; -13.50 units on a scale — p=0.612
Diabetes Mellitus
Primary: Patients With Morning (AM) Glucose Between 80-130 mg/dl on Day 2 and 3 — 10; 18; 14 participants
Breast Neoplasm
Primary: Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to…
Respiratory Distress Syndrome, Adult · Acute Lung Injury · Acute Respiratory Distress Syndrome
Primary: Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8 — 43; -241 pg/mL — p=0.37
Scoliosis
Primary: Posture Control of Head Position, Shoulder Position and Back Position — 5.5; 2.8 scores on a scale — p=<.0005
Thalassemia
Primary: Change in Lumbar Spine Bone Mineral Density (BMD) by DXA (Baseline to 18 Months) — 5.9; 1.5 Percent Change — p=0.13